<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00750932</url>
  </required_header>
  <id_info>
    <org_study_id>AOHP07-PD Pro-Muco</org_study_id>
    <secondary_id>DGS2007-0295</secondary_id>
    <secondary_id>NÂ° ID RCB:2007-A00511-52</secondary_id>
    <secondary_id>CPP: 2007-R17</secondary_id>
    <nct_id>NCT00750932</nct_id>
  </id_info>
  <brief_title>Biodistribution of Neutrophile Proteases in the Sputum of Patients Affected by Cystic Fibrosis</brief_title>
  <acronym>Pro-Muco</acronym>
  <official_title>Study of the Biodistribution of PMN Serine Proteases in Sputum of Patients Affected by Cystic Fibrosis: Towards New Anti-inflammatory Therapies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Tours</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the proposed project is to characterize the neutrophile proteases which&#xD;
      participate in the chronic inflammatory phenomenon associated with the cystic fibrosis and&#xD;
      which are responsible for the degradation of the lung tissue.&#xD;
&#xD;
      The respiratory failure which results from it is one of main causes of the fatal evolution of&#xD;
      this pathology but the anti-inflammatory therapies based on the use of antiproteases&#xD;
      targeting specifically the soluble elastase did not end, until now, in the hoped results.&#xD;
&#xD;
      The identification of the other noxious targets is a crucial element to give new orientations&#xD;
      to the anti-inflammatory strategies based on the administration of antiproteases which remain&#xD;
      a promising way.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">52</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>T</arm_group_label>
    <description>Control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>M</arm_group_label>
    <description>Minor with cystic fibrosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <description>Adult with cystic fibrosis</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood Sputum&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adults and children with cystic fibrosis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Man /woman older than 18 years (for adult and group)&#xD;
&#xD;
          -  Child aged 6 to 18 years (for child group)&#xD;
&#xD;
          -  Suffering from cystic fibrosis in stable condition, ie not having presented thrust&#xD;
             acute attack of the broncho-pulmonary or hospitalization for treatment of his illness&#xD;
             during the previous 2 weeks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  colonized by Burkholderia cepacia ou Stenotrophomonas maltophilia&#xD;
&#xD;
          -  non smoker (control group)&#xD;
&#xD;
          -  Without history or respiratory respiratory disease known (control group)&#xD;
&#xD;
          -  Antibiotic treatment and / or anti-inflammatory drug (NSAID or corticosteroids) in the&#xD;
             2 weeks prior to the inclusion in the study (control group)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrice DIOT, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tours Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHRU de Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>September 10, 2008</study_first_submitted>
  <study_first_submitted_qc>September 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2008</study_first_posted>
  <last_update_submitted>February 23, 2017</last_update_submitted>
  <last_update_submitted_qc>February 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

